COVID-19: How Orbis International is managing operations

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Investigators examined the connection between amblyopia, components of the metabolic syndrome and individual cardiometabolic diseases

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

The centre will facilitate research and access to resources for the 450,000 residents of the UK who are affected by sight and hearing loss